New Delhi, Aug 5 (PTI) Alkem Laboratories on Wednesday said it has launched Favipiravir under the brand name 'Alfluenza' in the country for the treatment of COVID-19.

COVID-19 cases are increasing significantly globally and India too is affected with around 50,000 new cases being added on a daily basis, Alkem Laboratories said in a statement.

Also Read | Samsung Unpacked 2020 Event Launch LIVE Updates: Galaxy Note 20 Series, Galaxy Z Fold 2, Galaxy Tab S7, Galaxy Buds Live & Galaxy Watch 3 Launched.

In this backdrop, the company has launched Favipiravir under the brand name Alfluenza in the country for the management of mild to moderate cases of COVID-19, it added.

Favipiravir is approved by the Drug Controller General of India (DCGI) for restricted emergency use. 

Also Read | Assam Lottery Results Today: Check Lucky Draw Results of Assam Future Kind, Assam Singam Green, Assam Kuil Gold on August 5, 2020 Online at assamlotteries.com.

Restricted use entails responsible medication where every patient must have signed informed consent before treatment initiation, Alkem said.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)